Vancomycin Continues to Dominate MRSA Treatment with up to 76 Percent of Surveyed Infectious Disease Specialists Indicating That They Use the Agent as First-Line Treatment for a Range of MRSA Infections
Approximately Ten Percent of Inpatients Receiving Antibiotic Treatment Have a Hospital-Acquired Bacterial Infection, According to Findings from Decision Resources and Arlington Medical Resources
BURLINGTON, Mass. & EXTON, Pa.--(BUSINESS WIRE)--May 23, 2011 - According to surveyed infectious disease specialists and internists as well as hospital patient-level medical data, Decision Resources and Arlington Medical Resources (AMR) find that vancomycin—which has experienced increasing usage over the past five years—continues to dominate treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Sixty to 76 percent of surveyed infectious disease specialists indicate that they use vancomycin as first-line treatment for bloodstream infections (BSIs), complicated skin and skin structure infections (cSSSIs) and hospital-acquired pneumonia (HAP) suspected to be or confirmed to involve MRSA.
Pfizer's Zyvox (linezolid) and Cubist's Cubicin (daptomycin) have been on the market for years and have steadily gained patient share and days of therapy with Zyvox having made notable gains in the treatment of HAP and Cubicin having gained usage for the treatment of bacteremia. However, despite increased usage, comparable efficacy to vancomycin in various indications and delivery advantages over vancomycin, neither Zyvox nor Cubicin have been able to supplant vancomycin as the preferred MRSA therapy in the hospital setting.
Study findings also reveal that surveyed infectious disease specialists consider sepsis and prosthetic joint infections to be the top most difficult-to-treat indications needing novel anti-MRSA therapies. Notably, 42 percent of surveyed infectious diseases specialists consider sepsis a top priority for novel agents to treat MRSA and 29 percent of surveyed internists agree. Additionally, patient level audit data of drug costs and usage reveal high antibiotic costs for sepsis and prosthetic joint infections owing to long treatment duration and use of premium-priced antibiotics.
“Sepsis is an indication for which there is little drug development and few treatment options and although drug development for this indication is a high risk, as evidenced by numerous unsuccessful development efforts to date, this indication is also one of significant commercial reward because of the high unmet need and limited competition,” said Decision Resources Analyst Charu Vepari, Ph.D. “Additionally, prosthetic joint infections due to MRSA are of equally high concern to infectious disease specialists and internists.”
Analysis of the overall patient population in the hospital antibiotics market reveals that ten percent of inpatients receiving antibiotic treatment have a hospital-acquired bacterial infection. Infections of the lower respiratory tract, urinary tract, skin/skin structure, gastrointestinal/biliary tract, and bloodstream are the most commonly treated indications in the hospital, regardless of where a patient acquires the infection. Additionally, half of all antibiotic-treated inpatients receive empiric therapy while only one-quarter receive therapy for a confirmed or documented infection. The remaining one-fourth of patients receives antibiotic therapy for surgical prophylaxis.
Nearly two-thirds of confirmed gram-positive infections treated in the hospital setting are caused by MRSA, methicillin-sensitive Staphylococcus aureus (MSSA), or S. epidermidis. Study findings also reveal that three-quarters of confirmed gram-negative infections treated in the hospital setting are caused by either E. coli, P. aeruginosa, or K. pneumoniae. Increasing resistance among these pathogens and limited treatment options creates significant opportunity for the development of novel therapies.
Clients who purchase the findings included in this press release will be eligible to attend our upcoming webinar on June 1 entitled Hospital Antibiotics: What are the Leading Indications and Preferred Therapies for the Treatment of Key Pathogens, the Unmet Needs and the Drivers of Formulary Decisions? Purchasing clients will also receive a complimentary PowerPoint presentation that combines key findings from the U.S. Physician & Payer Forum report entitled Hospital Anti-Infectives: Insights on the Uptake, Formulary Decision Making, and Reimbursement of Emerging Antibiotics in the United States and the Hospital Insight Series: Hospital Anti-Infectives report. Members of the media are welcome to attend this webinar; for more information, please contact Christopher Comfort at email@example.com.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Contact: Decision Resources, Inc.
Christopher Comfort, 781-993-2597
Posted: May 2011